Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics (NASDAQ: NRSN) has announced a collaboration with Dr. Ghazaleh Sadri-Vakili's NeuroEpigenetics Lab at Massachusetts General Hospital to study PrimeC, its lead ALS drug candidate. The research will utilize an in vitro model derived from post-mortem ALS brain tissue to examine PrimeC's neurotherapeutic effects, specifically targeting pathways related to TDP-43 accumulation and mitochondrial dysfunction. Preliminary findings will be presented by Dr. Zimri at the AD/PD 2023 Conference in Gothenburg, Sweden, scheduled for March 28 - April 1, 2023. PrimeC has previously shown promise in a Phase 2a clinical trial.

NeuroSense Therapeutics (NASDAQ: NRSN) announced that Dr. Shiran Zimri will present findings related to PrimeC at the AD/PD 2023 Conference in Gothenburg, Sweden, from March 28 - April 1, 2023. PrimeC is currently in Phase 2b trials for ALS, with topline results anticipated in H2 2023. Initial studies show PrimeC's efficacy in improving ALS-related biomarkers and tolerability. Additionally, a Phase 2 proof-of-concept study for Alzheimer's Disease is set to commence in H1 2023, focusing on the combined therapeutic strategy using ciprofloxacin and celecoxib, which may show promise in treating AD based on biomarker detections.

NeuroSense Therapeutics (Nasdaq: NRSN) announced its annual report for 2022, showcasing significant developments in its clinical trials and financials. The company is advancing its lead candidate PrimeC for ALS, with over 50% patient enrollment in the Phase 2b PARADIGM trial, expected to report topline results in H2 2023. Positive preliminary findings from a biomarker study in Alzheimer's disease prompted plans for a Phase 2 trial in H1 2023. However, R&D expenses surged by 108% to $6.4 million, and general administrative costs increased by 185% to $7.1 million, reflecting expanding operational activities. Cash reserves stood at $7.1 million.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced participation in the 17th annual BIO-Europe Spring conference on March 20-22, 2023 in Basel, Switzerland. Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will meet potential partners regarding the company's drug development pipeline. NeuroSense's lead drug, PrimeC, is in a global Phase 2b study for ALS, with results expected in H2 2023. Other programs include Alzheimer's and Parkinson's disease treatments, with key milestones expected in 2023.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on March 21, 2023, at 11:00 AM PST, and March 28, 2023, at 10:00 AM EST. The sessions will feature CEO Alon Ben-Noon and VP Nedira Salzman-Frenkel, focusing on the latest investor presentation and a live Q&A. Interested investors can register for the events, with limited spots available. Replays will be accessible later on the company's investor website. NeuroSense is dedicated to developing treatments for neurodegenerative diseases, addressing significant unmet medical needs in this area.

NeuroSense Therapeutics (NASDAQ: NRSN) recently shared a corporate update highlighting growth opportunities for 2023. The company anticipates topline results from its Phase 2b clinical trial in amyotrophic lateral sclerosis (ALS) in H2 2023, with enrollment already over 50% complete across four countries. Additionally, promising Alzheimer's disease biomarker results were announced, leading to a planned Phase 2 study in the first half of 2023. A Parkinson's disease biomarker study is also ongoing, with results expected soon. CEO Alon Ben-Noon expressed optimism about the company’s performance in 2022 and future milestones.

NeuroSense Therapeutics (NASDAQ: NRSN) has announced a collaboration with QuantalX Neuroscience to utilize Delphi-MD, a neurodiagnostic technology, in their upcoming Phase 2 clinical trial for Alzheimer's disease (AD). This trial is expected to commence in H1 2023 and aims to enhance early diagnosis and treatment of neurodegenerative diseases. Delphi-MD will provide objective measurements of brain function, supporting improved patient care. The partnership also anticipates using this technology in a future Phase 3 trial for PrimeC, NeuroSense's lead drug candidate for ALS treatment, pending successful Phase 2b trial results.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced regulatory approval from Germany's BfArM for its Clinical Trial Application to enroll patients in the PARADIGM study, a Phase 2b trial for PrimeC in treating amyotrophic lateral sclerosis (ALS). The study is set to include participants from Israel, Italy, Canada, and Germany, with over 50% of the 69 planned patients already enrolled. Topline results are anticipated in the second half of 2023. PrimeC combines two FDA-approved drugs aimed at addressing several mechanisms involved in ALS progression. The drug has previously met safety and efficacy endpoints in Phase 2a trials.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has received regulatory approval from Health Canada to initiate patient enrollment in its Phase 2b PARADIGM study for the treatment of amyotrophic lateral sclerosis (ALS) using its novel combination therapy, PrimeC. Over 50% of patients are already enrolled, with topline results expected in the second half of 2023. Following FDA's request for additional non-clinical data, NeuroSense has withdrawn its study protocol from the U.S. Investigational New Drug application and plans to align its strategy for a potential pivotal Phase 3 trial. PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, aims to target ALS progression effectively.